| Code | CSB-RA007466MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to MTX-474, targeting ephrin-B2 (EFNB2), a transmembrane ligand critical for bidirectional cell-cell communication through ephrin-Eph receptor signaling. EFNB2 plays essential roles in vascular development, angiogenesis, and arterial-venous specification during embryonic development. The protein regulates endothelial cell migration, vessel assembly, and vascular remodeling processes. Aberrant EFNB2 expression and signaling have been implicated in tumor angiogenesis, cancer progression, and metastasis across multiple malignancies, including glioblastoma, melanoma, and various carcinomas. Additionally, EFNB2 contributes to lymphangiogenesis and has been associated with inflammatory diseases and tissue repair mechanisms.
The reference antibody MTX-474 has been utilized in oncology research to investigate EFNB2-mediated tumor-stromal interactions and angiogenic pathways. This biosimilar provides researchers with a reliable tool for studying ephrin-B2 biology, exploring its role in vascular development and pathological neovascularization, and evaluating therapeutic strategies targeting ephrin-Eph signaling in cancer and vascular disorders.
There are currently no reviews for this product.